Goldman Sachs’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Goldman Sachs’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-459,900	Closed	-$53.2M	–	6001
2023 Q3	$53.2M	Sell	459,900 -847,900	-65%	-$91.1M	0.01%	1064
2023 Q2	$135M	Buy	+1,307,800	New	+$138M	0.03%	596
2022 Q1	–	Sell	-10,300	Closed	-$1.11M	–	7194
2021 Q4	$1.11M	Buy	+10,300	New	+$1.12M	﹤0.01%	4755
2018 Q1	–	Sell	-150,000	Closed	-$2.19M	–	6605
2017 Q4	$2.19M	Sell	150,000 -6,400	-4%	-$89.9K	﹤0.01%	3719
2017 Q3	$1.98M	Sell	156,400 -913,600	-85%	-$11.6M	﹤0.01%	3999
2017 Q2	$12.7M	Sell	1,070,000 -497,500	-32%	-$6.19M	﹤0.01%	2317
2017 Q1	$23.2M	Buy	1,567,500 +1,092,200	+230%	+$17.7M	0.01%	1784
2016 Q4	$7.69M	Buy	475,300 +40,300	+9%	+$731K	﹤0.01%	2665
2016 Q3	$7.89M	Hold	435,000	–	–	﹤0.01%	2647
2016 Q2	$7.16M	Sell	435,000 -465,000	-52%	-$7.52M	﹤0.01%	2576
2016 Q1	$14.9M	Sell	900,000 -22,200	-2%	-$388K	﹤0.01%	1930
2015 Q4	$20M	Sell	922,200 -370,900	-29%	-$7.22M	0.01%	1740
2015 Q3	$25.6M	Buy	1,293,100 +1,114,000	+622%	+$35.2M	0.01%	1539
2015 Q2	$6.22M	Buy	+179,100	New	+$5.47M	﹤0.01%	2768
2014 Q2	–	Sell	-35,000	Closed	-$529K	–	7232
2014 Q1	$529K	Hold	35,000	–	–	﹤0.01%	5234
2013 Q4	$267K	Buy	+35,000	New	+$189K	﹤0.01%	5774

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's HZNP Position: Q4 2023 in Review

Goldman Sachs sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 698,361 shares — an estimated $80.8M sold.

Goldman Sachs first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $161M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Goldman Sachs reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Goldman Sachs sold 698,361 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.8M.
Goldman Sachs first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
Goldman Sachs's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $161M in Q1 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.